1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Brookline Capital Acquisition Corp.

Brookline Capital Acquisition Corp.

BCAC
Brookline Capital Acquisition Corp.US flagNASDAQ Capital Market
22.71
USD
+12.72
- -
559.61MMarket Cap
Brookline Capital Acquisition Corp.
BCAC
(NASDAQ Capital Market)

Recent

price

22.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Similar Companies
HAZ Holdings, Inc. (HAZH)
Sagaliam Acquisition Corp. (SAGAR)
Austerlitz Acquisition Corporat (ASZ-WT)
Argus Capital Corp. (ARGUW)
Tuatara Capital Acquisition Corporation (TCACU)
Blue Room Acquisition Corp. Unit (IBLUU)
Business
Brookline Capital Acquisition Corp. was established in 2020 as a special purpose acquisition company, or SPAC. This entity initially sought to identify and merge with one or more businesses through a stock purchase, asset acquisition, recapitalization, or other similar transaction. The company’s strategic focus was primarily on opportunities within the vibrant life sciences sector. Headquartered in New York, New York, Brookline Capital Acquisition Corp. completed its business combination on July 29, 2022, with Apexigen, Inc., a clinical-stage biopharmaceutical firm. Following this reverse merger, the company was subsequently renamed Apexigen, Inc., and its shares began trading on Nasdaq under the new ticker symbol "APGN" as of August 1, 2022.